The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...

Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research ...

The Coalition for Epidemic Preparedness Innovations said it will invest $54.3 million with Moderna to fund a Phase 3 trial of ...

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...

Moderna (MRNA) stock is in focus as CEPI vaccine coalition agreed to invest up to $54.3M to support a late-stage trial for the company's bird flu shot. Read more here.

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...

Moderna Inc. will get as much as $54.3 million for a late-stage trial of its bird flu vaccine in a sign of how outside groups could help fill the void after the Trump administration slashed federal ...

Moderna Inc. will get as much as $54.3 million for a late-stage trial of its bird flu vaccine in a sign of how outside groups ...

Moderna will get $54M from a global coalition for a bird flu mRNA vaccine after the US canceled a $760M deal and cut mRNA ...

Another black mark against the bank’s remuneration report will see it join major rival Westpac in having raised the ire of ...